Tegsedi Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to improved understanding of hereditary amyloidosis, expansion of genetic testing programs, regulatory approvals for antisense therapies, growing specialist neurology networks, early clinical success of ttr suppression drugs.

The growth in the forecast period can be attributed to rising adoption of personalized genetic medicines, increasing demand for home-based treatment options, expansion of precision diagnostics, growing investment in rna therapeutics, advancements in long-term safety monitoring frameworks. Major trends in the forecast period include increasing adoption of rna-targeted therapies, growing preference for self-administered treatments, expansion of precision neurology medications, rising focus on disease-modifying therapies, enhanced patient monitoring and safety protocols.

The increasing adoption of personalized medicine is expected to drive the growth of the Tegsedi market in the coming years. Personalized medicine entails tailoring medical treatment according to an individual’s genetic makeup, lifestyle, and environment to achieve more effective results. The growing adoption of personalized medicine is fueled by advancements in genomic research, enhanced diagnostic tools, and the rising demand for more precise and effective therapies. Personalized medicine improves the efficacy and safety of Tegsedi by aligning treatment with the genetic and clinical profiles of patients with hereditary transthyretin-mediated amyloidosis, ensuring optimal therapeutic outcomes while minimizing potential risks. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the Food and Drug Administration (FDA) approved 16 new personalized therapies for patients with rare diseases in 2023, compared to six in 2022. Consequently, the increasing adoption of personalized medicine is propelling the growth of the Tegsedi market.

The increasing healthcare expenditure is expected to drive the growth of the Tegsedi market in the coming years. Healthcare expenditure refers to the total financial resources utilized by individuals, organizations, or governments for the prevention, treatment, and management of health conditions. Healthcare spending is rising due to advancements in medical technology, as new diagnostic tools, treatments, and innovative therapies often involve higher costs, resulting in greater overall healthcare spending. The growth in healthcare expenditure is enabling broader access to innovative therapies, supporting wider adoption of Tegsedi for patients with rare genetic disorders. For example, in December 2024, according to the Centers for Medicare & Medicaid Services, a U.S.-based agency overseeing the Medicare and Medicaid programs, U.S. healthcare expenditures in 2023 rose by 7.5%, reaching $4.9 trillion, or approximately $14,570 per person. Therefore, the increasing healthcare expenditure is contributing to the growth of the Tegsedi market.

In January 2024, Acino, a Switzerland-based pharmaceutical company, formed a partnership with Sobi for an undisclosed amount. Through this partnership, Acino and Sobi aim to increase access to essential therapies, including tegsedi, for patients with rare diseases in Kazakhstan, enhancing treatment availability in underserved regions. Sobi is a Sweden-based biopharmaceutical company that provides tegsedi.

Major companies operating in the tegsedi market are Ionis Pharmaceuticals Inc.

North America was the largest region in the tegsedi market in 2025. The regions covered in the tegsedi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tegsedi market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the tegsedi market by increasing costs of imported active pharmaceutical ingredients, oligonucleotide synthesis materials, specialized syringes, and cold-chain distribution components. North America and Europe are most affected due to dependence on cross-border sourcing of advanced biologic inputs, while Asia-Pacific faces higher costs for clinical-grade manufacturing materials. These tariffs contribute to higher therapy prices and impact patient access programs. However, they are also promoting domestic manufacturing of nucleic acid-based drugs and strengthening regional pharmaceutical supply chains.

The tegsedi market research report is one of a series of new reports that provides tegsedi market statistics, including tegsedi industry global market size, regional shares, competitors with a tegsedi market share, detailed tegsedi market segments, market trends and opportunities, and any further data you may need to thrive in the tegsedi industry. This tegsedi market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Tegsedi (inotersen) is a subcutaneous injection prescribed for treating polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis (hATTR), a condition in which amyloid proteins build up in tissues, causing nerve damage. It works by inhibiting the production of transthyretin (TTR) protein, which decreases amyloid deposits and helps relieve neuropathic symptoms. Given weekly through subcutaneous injection, it provides patients with a self-administered treatment option.

The primary indications for Tegsedi are neurological manifestations, cardiac involvement, and other conditions. Neurological manifestations refer to the symptoms and signs that result from dysfunction of the nervous system, which encompasses the brain, spinal cord, and peripheral nerves. The distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies. These serve various end-users such as hospitals, clinics, ambulatory care, and home care.

The tegsedi market consists of sales of subcutaneous injection, and prefilled syringe. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.